HALIX is a Netherlands-based biopharmaceutical CDMO specializing in viral vector and mammalian protein products. Operating from its state-of-the-art GMP facility at Leiden Bio Science Park, the company provides end-to-end development and manufacturing services for cell and gene therapies and biologics. HALIX supports the development and commercialization of therapies targeting life-threatening conditions, including cancer, COVID-19, influenza, and other infectious diseases.